This patient's presentation of acute hemolytic anemia (fatigue, jaundice, dark urine) triggered by an oxidative stressor (sulfonamide drug) in a person of Mediterranean descent is classic for glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD is the rate-limiting enzyme of the pentose phosphate pathway, which produces NADPH. NADPH is crucial for protecting red blood cells from oxidative damage.

In G6PD deficiency, oxidative stress (from drugs like primaquine) leads to the oxidation of sulfhydryl groups on hemoglobin, causing it to denature and precipitate within red blood cells. These intracellular precipitates are known as Heinz bodies. They are not visible on a standard Wright-Giemsa stain but can be seen with supravital stains like crystal violet. Macrophages in the spleen pluck out these inclusions, creating 'bite cells'.

The primary regulator of the pentose phosphate pathway is the intracellular concentration of NADP+. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme, is allosterically activated by its substrate NADP+ and strongly inhibited by its product, NADPH. A high NADP+/NADPH ratio signifies a need for more NADPH, thus stimulating the pathway.

The pentose phosphate pathway has two major products: NADPH and ribose-5-phosphate. While NADPH is used for reductive biosynthesis and antioxidant defense, ribose-5-phosphate is a critical precursor for the synthesis of purine and pyrimidine nucleotides, which are required for DNA and RNA synthesis. This is essential for rapidly dividing cells, such as those in a malignant tumor.

This patient has chronic granulomatous disease (CGD), an immunodeficiency caused by a defect in NADPH oxidase. This enzyme is crucial for the phagocytic oxidative (respiratory) burst, where it transfers an electron from NADPH to molecular oxygen to form the superoxide radical (O2-). This is the first step in generating reactive oxygen species used to kill ingested pathogens. The NADPH required for this process is generated primarily by the pentose phosphate pathway.

The pentose phosphate pathway is most active in tissues involved in reductive biosynthesis or those exposed to high levels of oxidative stress. The adrenal cortex has a very high rate of PPP activity because it requires large amounts of NADPH for the synthesis of steroid hormones from cholesterol. Other examples include the liver (fatty acid and cholesterol synthesis) and red blood cells (antioxidant defense). While erythrocytes (Choice C) rely exclusively on the PPP for NADPH, the overall flux is lower than in biosynthetic tissues like the adrenal cortex.

Glutathione reductase catalyzes the reduction of glutathione disulfide (oxidized glutathione, GSSG) to sulfhydryl-form glutathione (reduced glutathione, GSH). This reaction requires NADPH as a reducing agent. A deficiency in glutathione reductase would prevent the recycling of GSSG back to GSH, leading to the accumulation of GSSG and a depletion of the cell's primary antioxidant, GSH.

This patient is experiencing drug-induced hemolytic anemia, characteristic of G6PD deficiency. Dapsone is a well-known oxidative stressor. The underlying defect is the inability to produce sufficient NADPH via the pentose phosphate pathway. Without adequate NADPH, erythrocytes cannot maintain a supply of reduced glutathione to protect against oxidative damage from the drug, leading to hemoglobin denaturation (Heinz bodies), and subsequent hemolysis as splenic macrophages remove these inclusions ('bite cells').

When the cell needs NADPH but not ribose-5-phosphate, the oxidative phase of the PPP runs to produce NADPH. The resulting ribose-5-phosphate is then converted by the non-oxidative reactions (transketolase and transaldolase) into fructose-6-phosphate and glyceraldehyde-3-phosphate. These intermediates can then re-enter the glycolytic pathway to be recycled back to glucose-6-phosphate, allowing for continued production of NADPH.

The family history is classic for an X-linked recessive disorder, such as G6PD deficiency. The condition affects males (son, mother's brother) and is passed down from an unaffected carrier mother. Since males have only one X chromosome, they are more likely to be affected by recessive mutations on that chromosome. The father's negative history is consistent with this pattern, as he passes his Y chromosome to his son.